Researcher Spotlight: BOYU HU, MD THE UNIVERSITY OF UTAH Some patients with chronic lymphocytic leukemia (CLL) respond poorly to treatment due to genetic changes that affect primary DNA damage repair (DDR) mechanisms targeted by currently approved agents. Instead, the CLL…
Researcher Spotlight: Suchitra Sundaram, MD The Mount Sinai Icahn School of Medicine Over the past several years, targeted therapy with small molecule inhibitors and antibodies has replaced chemotherapy as the standard treatment for patients with chronic lymphocytic leukemia (CLL). Despite…
Researcher Spotlight: Boyu Hu, MD University of Utah/Huntsman Cancer Institute Gene mutations and chromosomal alterations found in relapsed/refractory chronic lymphocytic leukemia (CLL) makes the disease more resistant to currently approved therapies and prone to earlier relapses. While these gene changes…
Researcher Spotlight: Paolo Strati, MD The University of Texas Macrophages are large white blood cells that present antigens within the human immune system, an important step in signaling the immune system to attack disease,. Researchers are developing therapies which help increase the activity…
Researcher Spotlight: Rahul Lakhotia, MBBS National Institutes of Health Indolent lymphomas frequently require multiple lines of treatment as the disease recurs; the frequency of treatment makes it important to balance efficacy with potential toxicities (side effects). Dr. Lakhotia’s LCRMP project tests a new…
Researcher Spotlight: Teresa Sadras, PhD Beckman Research Institute City of Hope Though chronic lymphocytic leukemia (CLL) patients with indolent (slow-growing) forms of the disease have a high rates of long-term survival, patients with more aggressive forms of CLL have significantly…
A Discussion About Richter Transformation in Chronic Lymphocytic Leukemia with Tanya Siddiqi, MD, City of Hope How would you briefly describe chronic lymphocytic leukemia? Chronic lymphocytic leukemia (CLL) is a type of slow-growing non-Hodgkin lymphoma. It is a…